DUBLIN (WHTC) – Perrigo is going nowhere right now.
The board of the Irish generic drug maker Perrigo, whose operations are based in Allegan, unanimously rejected a $205 per share takeover bid by Mylan NV, saying in a statement that the proposal “substantially undervalues” Perrigo’s global business, deny full benefits of its “durable competitive position and compelling growth strategy,” and doesn’t take into account recent acquisitions and new products.
Perrigo also announced record revenue, income and operating cash flow for the third quarter of fiscal 2015.
